SUPPLEMENTARY MATERIAL




Figure:

- (A): Chest CT scan, axial non contrast section, at baseline: typical bilateral symmetrical hilar adenopathy and subcarinal adenopathy with calcification in the right hilar lymph nodes, upper right lobe macronodules and micronodules with typical perilymphatic and peribronchovascular distribution
- (B): Chest CT scan, axial non contrast section, after one year treatment by oral corticosteroids: pejorative evolution of lung sarcoidosis with consolidations with "galaxy sign", global stability of adenopathies
- (C): Chest CT scan, axial non contrast section, 6 months after the introduction of maraviroc: improvement of pulmonary involvement and decrease of lymph nodes size, with typical eggshell calcification in the left hilar lymph nodes, punctuate and nodular calcifications in the right hilar lymph nodes
- (D): Evolution of the patient's immunological parameters, in parallel with the evolution of sarcoidosislike granulomatosis, and therapeutic modifications. SQV = saquinavir, DDI = didanosin, TDF = tenofovir disoproxil, ETR = etravirin, RAL = raltegravir, MVC = maraviroc.

Lung function evaluated before and after both treatments FEV1: Forced expiratory volume in one seconde; FVC: Forced vital capacity; TLC: Total lung capacity; DLCO: Diffusing capacity for carbon monoxide; VA: Alveolar volume

J Investig Allergol Clin Immunol 2021; Vol. 31(1): 83-84 doi: 10.18176/jiaci.0537